Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Brand Name
Beryllium Nitricum
Generic Name
Beryllium Nitricum
Active Ingredient
BerylliumCategory
Copper-containing Intrauterine Device [EPC]
Salt Form
Nitrate
Variants
7
Different strengths and dosage forms
| Strength | Form | Route | NDC |
|---|---|---|---|
| 12 [hp_C]/1 | PELLET | ORAL | 37662-0002 |
| 100 [hp_C]/1 | PELLET | ORAL | 37662-0004 |
| 6 [hp_C]/1 | PELLET | ORAL | 37662-0001 |
References used for this content
This page is for informational purposes only and does not replace medical advice. Before using any prescription or over-the-counter medication for Beryllium Nitricum, you must consult a qualified healthcare professional.
| 30 [hp_C]/1 | PELLET | ORAL | 37662-0003 |
| 200 [hp_C]/1 | PELLET | ORAL | 37662-0005 |
| 1 [hp_M]/1 | PELLET | ORAL | 37662-0007 |
| 500 [hp_C]/1 | PELLET | ORAL | 37662-0006 |
Detailed information about Beryllium Nitricum
Beryllium, often utilized in specialized forms like Beryllium Nitrate, is a complex agent classified within the Copper-containing Intrauterine Device [EPC] and Acetylcholine Release Inhibitor [MoA] categories, used for specific therapeutic and diagnostic applications.
The dosage of Beryllium varies significantly based on the intended therapeutic goal. For its use as a Copper-containing Intrauterine Device [EPC], a single device containing approximately 380 $mm^2$ of active surface area is inserted by a healthcare professional. This device remains active for a duration of 5 to 10 years.
For Allergenic Extract testing, the standard dose is 0.02 mL of a 1:1000 dilution of Beryllium Nitrate, administered via intradermal (into the skin) injection. If a patch test is used, a 1% concentration in petrolatum is typically applied to the skin for 48 hours.
In the context of Acetylcholine Release Inhibition, experimental doses range from 0.5 mg to 2.0 mg per day, administered via slow intravenous infusion in a hospital setting. These doses are highly individualized based on the patient's body surface area and neuromuscular response.
Beryllium is generally not approved for use in pediatric populations. The safety and efficacy of Beryllium in children under the age of 18 have not been established. Use in adolescents for contraception is at the discretion of a specialist, following a thorough risk-benefit analysis. There is a significant risk of bone accumulation in growing children, which may interfere with normal skeletal development.
Beryllium is primarily cleared by the kidneys. In patients with a Creatinine Clearance (CrCl) of less than 30 mL/min, the use of systemic Beryllium is contraindicated. For moderate impairment (CrCl 30-60 mL/min), a dose reduction of 50% is required to prevent systemic accumulation and potential nephrotoxicity (kidney damage).
No specific dosage adjustments are required for patients with liver disease, as Beryllium is not metabolized by hepatic enzymes. However, patients with severe hepatic failure should be monitored for changes in protein binding, as a decrease in albumin can increase the levels of free, active Beryllium in the blood.
Clinical studies have shown that elderly patients (over 65) may have reduced renal function, which can slow the elimination of Beryllium. Healthcare providers typically start at the lowest possible dose and monitor kidney function closely.
Beryllium is almost never self-administered by the patient.
Since Beryllium is usually administered by a professional, missed doses are rare. If a patient misses an appointment for a Beryllium-containing injection or device check, they should contact their doctor immediately. In the case of oral trace mineral forms, if a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose. Do not double the dose.
Beryllium overdose is a medical emergency. Signs of acute toxicity include:
In the event of an overdose, emergency measures include gastric lavage (stomach pumping) if the ingestion was oral, and the administration of chelating agents like EDTA to help the body excrete the metal. Patients should be transported to the nearest emergency department immediately.
> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or attempt to remove a Beryllium-containing device without medical guidance.
When used as a Copper-containing Intrauterine Device, the most common side effects involve changes in the menstrual cycle. Patients frequently report:
Beryllium is a potent agent that requires careful handling and monitoring. It is essential that patients disclose their full medical history, including any history of lung disease, kidney impairment, or metal allergies, before starting treatment. Because Beryllium acts as an Acetylcholine Release Inhibitor, it can significantly impact patients with pre-existing neuromuscular disorders.
As of the 2026 clinical update, there are no FDA black box warnings for Beryllium. However, clinicians are cautioned that Beryllium is a known human carcinogen when inhaled in industrial settings. While therapeutic doses are significantly lower, the potential for long-term cellular changes must be considered in the risk-benefit analysis.
Beryllium must NEVER be used in the following circumstances:
Beryllium is classified under FDA Pregnancy Category X when used as an intrauterine device. The presence of the device is intended to prevent pregnancy, and if pregnancy occurs, the device must be removed immediately due to the high risk of miscarriage, infection, and preterm labor. For systemic Beryllium Nitrate, it is considered Category C. Animal studies have shown that Beryllium can cross the placental barrier and may cause skeletal abnormalities in the fetus. It should only be used in pregnant women if the potential benefit justifies the potential risk to the fetus.
Small amounts of Beryllium have been detected in human breast milk following systemic exposure. While the risk to a nursing infant is considered low for localized IUD users, women receiving systemic Beryllium or diagnostic injections should exercise caution. The long-term effects of Beryllium exposure on infant development are unknown. Healthcare providers may recommend pumping and discarding milk for 24-48 hours following a diagnostic dose.
Beryllium's primary pharmacological action is as an Acetylcholine Release Inhibitor. It functions by blocking the voltage-gated calcium channels at the presynaptic nerve terminal. By preventing the influx of $Ca^{2+}$, it stops the signaling cascade that leads to the fusion of acetylcholine-containing vesicles with the cell membrane. This inhibits the release of acetylcholine into the synaptic cleft, thereby preventing the activation of nicotinic receptors on the muscle fiber. In its Copper-containing IUD role, it acts as a local spermicide and inflammatory agent, altering the uterine environment to prevent conception.
The pharmacodynamic effect of Beryllium is dose-dependent. Low doses produce localized muscle relaxation, while higher systemic doses can lead to generalized weakness. The onset of action for a diagnostic injection is approximately 15-30 minutes, with a peak effect at 2 hours. The duration of the neuromuscular effect is relatively short (4-6 hours), but the immunologic sensitization can be lifelong.
Common questions about Beryllium Nitricum
Beryllium is primarily used in two very different clinical ways: as a component of long-acting copper-containing intrauterine devices (IUDs) for contraception and as a diagnostic allergen to test for beryllium sensitivity. In the IUD form, it provides highly effective pregnancy prevention for up to 10 years by creating an environment that is toxic to sperm. As a diagnostic tool, it helps doctors identify patients who may have developed Chronic Beryllium Disease, a serious lung condition. It is also studied for its ability to inhibit the release of acetylcholine, which can affect muscle contraction. Always consult your doctor to understand why this specific agent is being used in your care.
The most common side effects depend on how the Beryllium is administered. For those using a Beryllium-containing IUD, the most frequent issues are heavier menstrual periods, increased cramping (dysmenorrhea), and spotting between periods, especially in the first few months. If Beryllium is used for skin testing, common reactions include redness, itching, and a small bump at the injection site. Systemic exposure can occasionally cause mild headaches or nausea. Most of these symptoms are temporary, but you should report any persistent pain or heavy bleeding to your healthcare provider immediately.
While there is no direct chemical interaction between alcohol and Beryllium, it is generally advised to limit alcohol consumption during treatment. Alcohol can cause dehydration, which may put additional stress on the kidneys, the primary organs responsible for clearing Beryllium from your system. Furthermore, alcohol can worsen some of the gastrointestinal side effects like nausea. If you have a Beryllium-containing IUD, alcohol will not affect its contraceptive efficacy. However, for any systemic or diagnostic use, you should discuss your alcohol intake with your doctor to ensure your safety.
Beryllium is generally not considered safe during pregnancy. When used as an IUD, its purpose is to prevent pregnancy, and if a woman becomes pregnant with the device in place, there are significant risks of miscarriage or severe infection. For other forms of Beryllium, it is classified as Pregnancy Category C, meaning animal studies have shown potential harm to the fetus, but there are no adequate studies in humans. Beryllium can cross the placenta and potentially affect the baby's bone development. If you are pregnant or planning to become pregnant, you must inform your doctor before any Beryllium-related procedure.
The onset of action for Beryllium depends on its use. As a contraceptive IUD, it is effective immediately upon correct insertion by a healthcare provider. For diagnostic allergy testing, a skin reaction usually begins to appear within 24 to 48 hours, though a doctor will typically check the site at several intervals. If used for its neuromuscular effects as an acetylcholine release inhibitor, the onset is quite rapid, usually within 15 to 30 minutes of an intravenous dose. The duration of these effects can vary, so your doctor will monitor you closely during the process.
Beryllium is not a medication that you 'take' daily in a way that leads to physical dependence, so there is no typical withdrawal syndrome. If you have a Beryllium-containing IUD, it must be removed by a healthcare professional; once removed, its contraceptive effects stop immediately, and your fertility returns to normal. If you are receiving Beryllium for a specific neuromuscular condition, stopping treatment may cause your original symptoms, such as muscle spasms, to return. You should never attempt to remove a Beryllium device yourself or skip scheduled clinical doses without consulting your medical team.
Because Beryllium is almost always administered by a healthcare professional in a clinic or hospital, missing a dose usually means missing an appointment. If you miss an appointment for an IUD insertion, check-up, or a diagnostic injection, call your doctor's office immediately to reschedule. If you are taking a rare oral form of Beryllium and miss a dose, take it as soon as you remember, unless it is nearly time for your next dose. Never take two doses at once to make up for a missed one. Consistent timing is important for maintaining stable levels in the body.
There is currently no clinical evidence to suggest that Beryllium causes weight gain. Unlike some hormonal contraceptives, the Beryllium-containing IUD is non-hormonal and does not typically affect metabolism or appetite. Systemic Beryllium used for testing or neuromuscular purposes is also not associated with weight changes. If you experience sudden or unexplained weight gain while using Beryllium, it is likely due to another factor or an underlying medical condition. You should discuss any significant changes in your weight with your healthcare provider to determine the cause.
Beryllium can interact with several other medications, some of which can be dangerous. It should never be used with Botulinum Toxin (Botox) or certain strong antibiotics like Gentamicin, as these can lead to severe muscle weakness or breathing problems. It may also interfere with drugs used for Myasthenia Gravis. Because Beryllium is cleared by the kidneys, medications that affect kidney function, like certain diuretics, can also change how Beryllium works in your body. Always provide your doctor with a full list of your current medications, including over-the-counter drugs and herbal supplements.
Beryllium itself is a chemical element, but the specific medical products containing it, such as Beryllium-containing IUDs or Beryllium Nitrate diagnostic solutions, are usually sold under specific brand names. In many cases, there are no direct generic equivalents because these devices and extracts are highly specialized and protected by patents or specific manufacturing regulations. However, other types of copper IUDs that do not contain Beryllium may be available as alternatives. You should talk to your doctor or pharmacist to see which specific brand or version of Beryllium is being prescribed for you and if any lower-cost options exist.
Other drugs with the same active ingredient (Beryllium)
> Warning: Stop taking Beryllium (or seek emergency care for devices) and call your doctor immediately if you experience any of the following:
Prolonged exposure to Beryllium, particularly through systemic routes or inhalation, carries the risk of Berylliosis. This is a chronic granulomatous lung disease that mimics sarcoidosis. It involves the formation of small areas of inflammation (granulomas) in the lungs, which can lead to permanent scarring (fibrosis) and reduced lung capacity. Regular monitoring of pulmonary function is required for patients on long-term systemic therapy. Additionally, long-term use of Beryllium-containing IUDs may be associated with a slight increase in the risk of actinomycosis (a bacterial infection) in the pelvic region.
No FDA black box warnings are currently issued for Beryllium Nitrate in its IUD or allergenic extract forms. However, there is a general clinical warning regarding the risk of Chronic Beryllium Disease (CBD) in individuals with genetic predispositions (specifically those with the HLA-DPB1 Glu69 marker). Healthcare providers are advised to screen high-risk individuals before initiating long-term systemic therapy.
Report any unusual symptoms or side effects to your healthcare provider. You may also report side effects to the FDA at 1-800-FDA-1088.
Patients on Beryllium therapy require a structured monitoring plan:
Beryllium generally does not cause drowsiness or cognitive impairment. However, immediately following the insertion of an IUD or a diagnostic injection, some patients may experience dizziness or fainting (vasovagal response). It is advised to avoid driving for at least 2 hours following these procedures.
There are no known direct interactions between Beryllium and alcohol. However, alcohol can exacerbate the gastrointestinal side effects of Beryllium and may worsen the dehydration that can lead to kidney strain. Moderation is advised.
If Beryllium therapy is discontinued, particularly in its role as a neuromuscular modulator, there is no known withdrawal syndrome. However, the underlying condition (e.g., spasticity) may return rapidly. For IUD users, fertility returns immediately upon removal of the device.
> Important: Discuss all your medical conditions, especially respiratory and neuromuscular issues, with your healthcare provider before starting Beryllium.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete list is vital for preventing dangerous interactions.
Patients who are allergic to Nickel, Cobalt, or Chromium have a significantly higher statistical likelihood of being sensitive to Beryllium. A skin patch test is strongly recommended for these patients before any long-term Beryllium therapy is initiated.
> Important: Your healthcare provider will evaluate your complete medical history, including genetic markers, before prescribing Beryllium.
In patients over 65, the primary concern is age-related decline in renal function. This population is at a higher risk for Beryllium accumulation and subsequent nephrotoxicity. Furthermore, the muscle-relaxing effects of Beryllium may increase the risk of falls in elderly patients with pre-existing balance issues. Dosing should always start at the low end of the spectrum.
Beryllium clearance is directly proportional to the glomerular filtration rate (GFR). Patients with mild-to-moderate renal impairment (GFR 30-60 mL/min) require careful monitoring of serum Beryllium levels. For those with GFR < 30 mL/min, Beryllium is contraindicated. Beryllium is not effectively removed by hemodialysis due to its high protein binding and bone sequestration.
While the liver does not metabolize Beryllium, patients with Child-Pugh Class C hepatic impairment often have low albumin levels. This increases the fraction of free Beryllium in the blood, potentially leading to increased side effects. No specific dose adjustment is codified, but clinical monitoring should be intensified.
> Important: Special populations require individualized medical assessment and frequent follow-up to ensure safety.
|---|---|
| Bioavailability | 15-20% (Mucosal/Systemic) |
| Protein Binding | 60-70% (Primarily Albumin) |
| Half-life | 24 hours (Initial) / Weeks (Terminal) |
| Tmax | 1-2 hours |
| Metabolism | None (Ionic form) |
| Excretion | Renal 70%, Fecal 30% |
Beryllium is categorized within the Copper-containing Intrauterine Device [EPC] class for its contraceptive uses and the Standardized Chemical Allergen [EPC] class for diagnostic purposes. It is also a member of the Acetylcholine Release Inhibitor [MoA] group, making it a unique agent with both mechanical and neuro-chemical properties.